146 related articles for article (PubMed ID: 29509907)
41. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
[TBL] [Abstract][Full Text] [Related]
42. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
[TBL] [Abstract][Full Text] [Related]
43. Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
Otto C; Hofmann J; Ruprecht K
Med Hypotheses; 2016 Jun; 91():109-113. PubMed ID: 27142157
[TBL] [Abstract][Full Text] [Related]
44. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic Performance and Comparative Evaluation of the Architect, Liaison, and Platelia Epstein-Barr Virus Antibody Assays.
Park Y; Park BG; Ha J; Kim HS
Ann Lab Med; 2018 Sep; 38(5):458-465. PubMed ID: 29797817
[TBL] [Abstract][Full Text] [Related]
46. Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.
Harada S; Kamata Y; Ishii Y; Eda H; Kitamura R; Obayashi M; Ito S; Ban F; Kuranari J; Nakajima H; Kuze T; Hayashi M; Okabe N; Senpuku H; Miyasaka N; Nakamura Y; Kanegane H; Yanagi K
Clin Diagn Lab Immunol; 2004 Jan; 11(1):123-30. PubMed ID: 14715558
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
50. Demonstration of EBNA (Epstein-Barr virus nuclear antigen) antibodies of different immunoglobulin classes.
Czeglédy J; Gergely L; Váczi L; Szalka A
Acta Microbiol Acad Sci Hung; 1978; 25(4):237-43. PubMed ID: 224651
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of antibodies to Epstein-Barr virus in Italian patients with nasopharyngeal carcinoma.
Cevenini R; Donati M; Caliceti U; Moroni A; Tamba I; Rumpianesi F
J Infect; 1986 Mar; 12(2):127-31. PubMed ID: 3009628
[TBL] [Abstract][Full Text] [Related]
52. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
[TBL] [Abstract][Full Text] [Related]
53. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
Jiang SQ; Liu Q
Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
56. Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma.
Liu MY; Shih YY; Chou SP; Chen CJ; Sheen TS; Yang CS; Chen JY
J Med Virol; 1998 Nov; 56(3):179-85. PubMed ID: 9783682
[TBL] [Abstract][Full Text] [Related]
57. [Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].
De Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):618-20. PubMed ID: 22854635
[TBL] [Abstract][Full Text] [Related]
58. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
59. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients.
Rasmussen NS; Draborg AH; Nielsen CT; Jacobsen S; Houen G
Scand J Rheumatol; 2015; 44(2):143-9. PubMed ID: 25562120
[TBL] [Abstract][Full Text] [Related]
60. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
